BiotechTube
NG BIOTECH

NG BIOTECH

Guerande, France· Est.
ngbiotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

NG Biotech is a commercial-stage diagnostics company developing rapid, multiplex tests for critical infectious disease threats, particularly antimicrobial-resistant pathogens. Its core asset is a proprietary immunoassay platform that delivers qualitative results in minutes from small samples like a drop of blood. The company recently gained significant validation with FDA Breakthrough Device Designation for two tests targeting WHO-critical drug-resistant pathogens, positioning it as a key player in the global AMR diagnostic market. With ISO-certified manufacturing facilities in France, NG Biotech serves human health, veterinary, and biodefense sectors.

Infectious DiseasesAntimicrobial ResistanceWomen's Health

Technology Platform

Proprietary patented immunoassay platform for qualitative, multiplex point-of-care diagnostics. Delivers results in minutes from small samples (e.g., a drop of blood, urine).

Opportunities

The global AMR crisis creates a massive, urgent need for rapid diagnostics, supported by WHO and government initiatives.
FDA Breakthrough Designation accelerates U.S.
market entry, the world's largest healthcare market.
The versatile platform allows expansion into veterinary health, custom development, and other infectious disease areas.

Risk Factors

Regulatory risk remains, as FDA clearance is not guaranteed despite the Breakthrough Designation.
The company faces intense competition in the rapid diagnostics market from both immunoassay and molecular players.
Successful commercialization depends on proving clinical utility, achieving reimbursement, and displacing existing lab workflows.

Competitive Landscape

NG Biotech competes in the rapid infectious disease diagnostics space against large, established IVD companies (e.g., Abbott, Roche, BD) and specialized AMR diagnostic firms. Its differentiation lies in its multiplex immunoassay platform focused on specific resistance mechanisms for POC use. It faces competition from faster-evolving but often more expensive molecular PCR-based platforms.

More companies in Diagnostics & Precision Medicine →More companies in France →